Q1 2025 · 13F-HR
Foresite Capital Management VI LLCholdings as filed
Filed 2025-05-15 · accession 0001104659-25-049404
$182.5M
Reported value
14
Positions
2025-03-31
Period end
The Brief · Foresite Capital Management VI LLC · Q1 2025
AI · grounded in 13F
Foresite Capital Management VI LLC reported no changes to its 13F holdings for 2025-03-31 relative to 2024-12-31.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG Oncology, Inc. | $54.4M | 29.8% | 2,221,474 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc | $25.8M | 14.1% | 4,202,670 | Common | SOLE |
| 152309100 | CNTA | Centessa Pharmaceuticals Inc | $18.0M | 9.87% | 1,253,379 | Common | SOLE |
| 75382E109 | — | Rapt Therapeutics Inc | $15.3M | 8.35% | 12,500,000 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics Inc | $14.8M | 8.09% | 365,000 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics Inc | $12.9M | 7.05% | 585,000 | Common | SOLE |
| 055477103 | BCAX | Bicara Therapeutics Inc | $12.4M | 6.78% | 950,000 | Common | SOLE |
| 86366E106 | GPCR | Structure Therapeutics Inc | $7.3M | 3.98% | 420,000 | Common | SOLE |
| 019770106 | ALLO | Allogene Therapeutics Inc | $5.0M | 2.76% | 3,448,275 | Common | SOLE |
| 221015100 | CRVS | Corvus Pharmaceuticals Inc | $5.0M | 2.75% | 1,581,233 | Common | SOLE |
| 230031106 | CGEM | Cullinan Therapeutics Inc | $4.8M | 2.63% | 634,558 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics Inc | $4.0M | 2.19% | 146,332 | Common | SOLE |
| G1933S101 | CASIF | Casi Pharmaceuticals Inc | $2.9M | 1.57% | 1,329,383 | Common | SOLE |
| 92790C104 | VRDN | Viridian Therapeutics, Inc | $26,610 | 0.01% | 1,974 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.